News & Topics
News&Topics

2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011 / 2010 / 2009 / 2008 / 2007 / 2006 / 2005

2019.12.10
Onconova Announces Data from the INSPIRE Trial and Updated Oral Rigosertib Data at the American Society of Hematology (ASH) 2019 Annual Meeting
2019.12.09
Onconova Announces Collaboration with Inceptua for Pre-approval Access to Anti-cancer Drug Rigosertib
2019.12.02
Monthly Exercise Status of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2019.12.02
Analyst Report[Full report] (Shared Research)
2019.11.27
Notice of the Large Volume Exercise of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2019.11.25
Notice of the Large Volume Exercise of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2019.11.12
Notice of Instruction for Front-Loading Exercise of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment and Conclusion of Amendment Agreement
2019.11.08
Analyst Report[Update report] (Shared Research)
2019.11.08
Summary of Financial Statements for the first nine months of fiscal year ending December 31, 2019 [Japanese GAAP] (Non-consolidated)
2019.11.08
Notice Concerning Non-operating Expenses
2019.11.08
Onconova Announces Presentation on Rigosertib in Myelodysplastic Syndromes at 2019 ASH Annual Meeting & Exposition
2019.11.07
Analyst Report[Follow-up Report] (Fair Research)
2019.11.05
SymBio Announces Achievement of Primary Endpoint (Overall Response Rate) in Phase 3 Clinical Trial of TREAKISYM in relapsed/refractory diffuse large B-cell lymphoma
2019.10.25
Onconova Provides Update on the Global Phase 3 INSPIRE Trial of Rigosertib in Myelodysplastic Syndromes and on Future Clinical Trial Plans
2019.10.18
Notice Regarding Inappropriate Conduct of Clinical Trial Monitor
2019.10.01
SymBio Announces Exclusive Global License Agreement with Chimerix for Antiviral Drug, Brincidofovir
2019.09.26
SymBio Submits New Drug Application for TREAKISYM Ready-To-Dilute (RTD) Formulation
2019.09.25
Analyst Report[Full report] (Shared Research)
2019.09.18
Progress (LPLV) of Phase 3 Clinical Trial of the Anti-cancer Drug TREAKISYM in relapsed/refractory diffuse large B-cell lymphoma
2019.08.07
Analyst Report[Update report] (Shared Research)
2019.08.07
Revision to Earnings Forecasts for FY 2019 and Mid-Range Plan (FY 2019 to FY 2022)
2019.08.07
Summary of Financial Results for the First Half of Fiscal Year Ending December 31, 2019 [Japanese GAAP] (Non-consolidated)
2019.08.07
Notice Concerning Non-operating Expenses
2019.07.19
Notice Regarding Sale of Fractional Shares Due to Reverse Stock Split
2019.07.01
Analyst Report[Full report] (Shared Research)
2019.06.17
Completion, Monthly Exercise Status and Large Volume Exercise of the 46th Stock Acquisition Rights(with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2019.06.13
Notice of the Large Volume Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2019.06.12
Notice of Change (Resignation) of Representative Director and Appointment of Corporate Officer
2019.06.11
Notice of the Large Volume Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2019.06.03
Monthly Exercise Status of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2019.05.28
Notice of the Large Volume Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2019.05.22
Launch of "Regenerative Medicine" Products that can be used with the anti-cancer drug TREAKISYM as a pretreatment agent
2019.05.14
Analyst Report[Update report] (Shared Research)
2019.05.14
Summary of Financial Results for the First Quarter of Fiscal Year Ending December 31, 2019 [Japanese GAAP] (Non-consolidated)
2019.05.14
Notice Concerning Non-operating Expenses
2019.05.07
Monthly Exercise Status of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2019.04.22
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors
2019.04.22
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees
2019.04.18
Notice of the Large Volume Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2019.04.17
Analyst Report[Corporate outlook] (EDISON)
2019.04.16
Analyst Report[Basic Report] (Fair Research)
2019.04.12
Notice of the Large Volume Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2019.04.10
Notice of the Large Volume Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2019.04.10
First patient enrolled in Clinical Trial for TREAKISYM Rapid Infusion Liquid Formulation
2019.04.08
Completion of Patient Enrollment in the Phase 3 Clinical Trial of the Anti-cancer Drug TREAKISYM for the Indication of relapsed/refractory diffuse large B-cell lymphoma
2019.04.03
Analyst Report[Full report] (Shared Research)
2019.04.01
Monthly Exercise Status of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2019.04.01
Onconova Announces Over 75 Percent of Planned Enrollment Achieved in Phase 3 INSPIRE Study of Rigosertib
2019.03.29
Notice of Shareholder Voting Results for the 14th Ordinary General Meeting of Shareholders
2019.03.28
Notice Regarding Reverse Stock Split and Amendment to the Articles of Incorporation
2019.03.28
Notice Concerning the Issuance of Stock Acquisition Rights to Directors
2019.03.28
Notice Concerning the Issuance of Stock Acquisition Rights to Employees
2019.03.28
Notice of Board of Director, Audit & Supervisory Board, and Corporate Officer Appointments
2019.03.26
TREAKISYM Approved for use as a Pretreatment to Adoptive T-Cell Therapy
2019.03.14
Notice of Instruction for Front-Loading Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2019.03.11
Information on Shareholders' Meeting: Updated the Page
2019.03.05
(Correction Notice of Press Release) Notice Regarding Reverse Stock Split and Amendment to the Articles of Incorporation
2019.02.28
Notice Regarding Reverse Stock Split and Partial Amendment to Articles of Incorporation
2019.02.28
Notice concerning Nominations for the Board of Directors / the Audit & Supervisory Board / and Substitute Member for the Audit & Supervisory Board
2019.02.07
SymBio's Mid-Range Plan: FY 2019 to FY 2022 (Four Years)
2019.02.07
Notice Concerning Non-operating Expenses
2019.02.07
Summary of Financial Statements for the Fiscal Year Ended December 31, 2018[Japanese GAAP] (Non-consolidated)